The Global Precision Medicine Market Growth is Driven by Expanding Adoption of Genomic-Based Therapies and AI-Powered Diagnostics.
Austin, Nov. 24, 2025 (GLOBE NEWSWIRE) — Precision Medicine Market Size & Growth Analysis:
According to SNS Insider, the Precision Medicine Market is estimated at USD 118.69 billion in 2025 and is projected to reach USD 400.67 billion by 2033, growing at a CAGR of 16.45% from 2026 to 2033. The U.S. Precision Medicine Market is projected to grow from USD 45.36 billion in 2025 to USD 153.45 billion by 2033 at a CAGR of 16.48%.
The Precision Medicine Market continues to expand as healthcare systems adopt personalized treatment methods grounded in genetic profiling, advanced biomarkers, and AI-powered diagnostic tools. Precision medicine enables tailored therapies for individual patients, improving treatment accuracy and reducing adverse reactions. This rising shift toward targeted care is reshaping patient management, particularly in oncology, rare disease treatment, and chronic disorder prevention.
Get a Sample Report of Precision Medicine Market Forecast: https://www.snsinsider.com/sample-request/8734
Healthcare providers are investing in genomic sequencing technologies, predictive analytics, and clinical decision support systems that deliver real-time insights for diagnosis and treatment optimization. With patients seeking more individualized healthcare solutions and organizations transitioning toward data-driven clinical models, precision medicine is quickly becoming a core framework for modern medical innovation.
Key Precision Medicine Companies Profiled
- Illumina
- Thermo Fisher Scientific
- Roche
- Pfizer
- Novartis
- AstraZeneca
- Johnson & Johnson
- Merck & Co.
- Abbott Laboratories
- Medtronic
- Qiagen
- Guardant Health
- Myriad Genetics
- Foundation Medicine
- Tempus Labs
- Caris Life Sciences
- Exact Sciences
- Agilent Technologies
- Siemens Healthineers
- 23andMe
Segmentation Analysis:
By Type
Targeted Therapy held the largest market share of 45.72% in 2025 due to its high acceptance in Oncology, Cardiovascular and Chronic disease management. Pharmacogenomics is expected to grow at the fastest CAGR of 18.27% driven by increasing usage of personalized drug-response testing, genomic-guided prescriptions, and rising awareness among healthcare professionals and patients.
By Technology
Next-Generation Sequencing (NGS) dominated with a 38.91% share in 2025 due to its high acceptance in Oncology, Cardiovascular and Chronic disease management. CRISPR is projected to expand at the fastest CAGR of 19.05% due to innovations in gene therapy, clinical trials and rising use of research for rare genetic diseases.
By Application
Oncology accounted for the highest market share of 42.36% in 2025 due to the wide usage of targeted drugs and companion diagnostics. Rare & Genetic Disorders are projected to record the fastest CAGR of 18.78% owing to genomic sequencing, personalized treatment plans, and the increasing investment for development of drugs for rare diseases.
By End-User
Hospitals held the largest share of 40.58% in 2025 on account of infrastructure development, trained professionals and integrated diagnosis systems. Research Institutes are expected to grow at the fastest CAGR of 17.92% due to increasing adoption of AI assisted diagnostics, clinical trials and application for innovation in personalized medicine applications.
Need any customization research on the Precision Medicine Market? Enquire Now: https://www.snsinsider.com/enquiry/8734
Regional Insights:
The North America region dominated the Precision Medicine Market with a 52.48% share in 2025, serving more than 7.5 million patients comprising oncology, cardiovascular conditions, and rare genetic disorders.
Asia Pacific is the fastest growing in Precision Medicine Market with a CAGR of 18.55%, owing to rising usage of targeted treatments, genome testing and AI-based diagnosis. In 2025, China provided more than 3.5 million precision therapies and India treated nearly 1.8 million patients.
Recent Developments:
- In September 2025, Illumina partnered with pharmaceutical companies to develop KRAS companion diagnostics, aiming to improve personalized cancer therapies and accelerate targeted treatment adoption across oncology patients.
- In June 2025, Thermo Fisher launched its Orbitrap Astral Zoom and Excedion Pro mass spectrometers, providing higher speed and sensitivity for biopharma applications, omics research, and advanced diagnostic workflows.
Exclusive Sections of the Report (The USPs):
- REGULATORY & REIMBURSEMENT ADOPTION METRICS – helps you understand approval volumes, regional approval timelines, reimbursement coverage strength, and policy incentives shaping precision therapy accessibility.
- THERAPY EFFECTIVENESS & TREATMENT PERFORMANCE INDEX – helps you evaluate therapy duration, response/success rates across disease categories, market share shifts between emerging and established therapies, and adherence to genomic-driven treatment plans.
- ECOSYSTEM COLLABORATION & STRATEGIC ENGAGEMENT SCORE – helps you analyze the scale of public-private collaborations, cross-industry partnerships, and investments in precision medicine infrastructure across major regions.
- CLINICAL TRIAL PIPELINE & SUCCESS METRICS – helps you track the volume of active trials, patient enrollment trends, approval success rates, and emerging collaborative trial initiatives fueling innovation.
- POLICY & INCENTIVE-DRIVEN MARKET MOMENTUM – helps you assess how government-led pilot programs, tax incentives, grants, and regional support mechanisms accelerate the adoption of precision medicine solutions.
Purchase Single User PDF of Precision Medicine Market Report: https://www.snsinsider.com/checkout/8734
Precision Medicine Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 118.69 Billion |
| Market Size by 2033 | USD 400.67 Billion |
| CAGR | CAGR of 16.45% From 2026 to 2033 |
| Base Year | 2025 |
| Forecast Period | 2026-2033 |
| Historical Data | 2022-2024 |
| Key Segments | • By Type (Targeted Therapy, Genomic Medicine, Pharmacogenomics, Companion Diagnostics, Others)
• By Technology (Next-Generation Sequencing, PCR & qPCR, CRISPR, Bioinformatics, Others) • By Application (Oncology, Cardiovascular Diseases, Rare & Genetic Disorders, Neurological Disorders, Others) • By End User (Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical & Biotech Companies, Others) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Access Complete Report Details of Precision Medicine Market Analysis & Outlook: https://www.snsinsider.com/reports/precision-medicine-market-8734
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.
